- Home
- Publications
- Publication Search
- Publication Details
Title
Nonalcoholic Fatty Liver Disease
Authors
Keywords
-
Journal
HYPERTENSION
Volume 75, Issue 2, Pages 275-284
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2019-12-23
DOI
10.1161/hypertensionaha.119.13419
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis
- (2019) Jingjing Cai et al. HEPATOLOGY
- Association between ADIPOQ G276T and C11377G polymorphisms and the risk of non-alcoholic fatty liver disease: An updated meta-analysis
- (2019) Mengwei Liu et al. Molecular Genetics & Genomic Medicine
- Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice
- (2019) Jiang-Hua Zhou et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Immune mechanisms of salt-sensitive hypertension and renal end-organ damage
- (2019) David L. Mattson Nature Reviews Nephrology
- Innate immune regulatory networks in hepatic lipid metabolism
- (2019) Lan Bai et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- The degree of hepatic steatosis associates with impaired cardiac and autonomic function
- (2019) David Houghton et al. JOURNAL OF HEPATOLOGY
- Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension
- (2019) Giovanni Musso et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The liver as an endocrine organ - linking NAFLD and insulin resistance
- (2019) Matthew J Watt et al. ENDOCRINE REVIEWS
- Unexpected Rapid Increase in the Burden of Nonalcoholic Fatty Liver Disease in China From 2008 to 2018: A Systematic Review and Meta‐Analysis
- (2019) Feng Zhou et al. HEPATOLOGY
- Impact of different ectopic fat depots on cardiovascular and metabolic diseases
- (2019) Daniele Ferrara et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Microbiome Signatures Associated with Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease
- (2019) Jeffrey B. Schwimmer et al. GASTROENTEROLOGY
- Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment
- (2019) Ming-Ming Chen et al. GENE EXPRESSION
- Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis
- (2019) Jia-Zhen Zhang et al. GENE EXPRESSION
- Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease
- (2019) Ze Chen et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Targeting TLR4 signaling pathways: can therapeutics pay the toll for hypertension?
- (2018) Kenia Pedrosa Nunes et al. BRITISH JOURNAL OF PHARMACOLOGY
- FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1–7) Axis in Mice
- (2018) Xuebo Pan et al. Cell Metabolism
- Nonalcoholic fatty liver disease and hypertension
- (2018) Dimitrios Oikonomou et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Time to step-up the fight against NAFLD
- (2018) Xiao-Jing Zhang et al. HEPATOLOGY
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
- (2018) Amedeo Lonardo et al. JOURNAL OF HEPATOLOGY
- Bidirectional association between non-alcoholic fatty liver disease and hypertension from Dongfeng-Tongji cohort study
- (2018) Peiyi Liu et al. Journal of the American Society of Hypertension
- Progress and challenges in the prevention and control of nonalcoholic fatty liver disease
- (2018) Jingjing Cai et al. MEDICINAL RESEARCH REVIEWS
- The gut–liver axis and the intersection with the microbiome
- (2018) Anupriya Tripathi et al. Nature Reviews Gastroenterology & Hepatology
- Tollip Negatively Regulates Vascular Smooth Muscle Cell–Mediated Neointima Formation by Suppressing Akt‐Dependent Signaling
- (2018) Hong Zhi et al. Journal of the American Heart Association
- Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases
- (2018) Jingjing Cai et al. Annual Review of Pathology-Mechanisms of Disease
- Epigenetic processing in cardiometabolic disease
- (2018) Sarah Costantino et al. ATHEROSCLEROSIS
- The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension
- (2018) Revathy Carnagarin et al. BRITISH JOURNAL OF PHARMACOLOGY
- The fatty liver index (FLI) and incident hypertension: a longitudinal study among Chinese population
- (2018) Kena Zhou et al. Lipids in Health and Disease
- Metabolites as regulators of insulin sensitivity and metabolism
- (2018) Qin Yang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease
- (2018) Jingjing Cai et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Inflammation as a Regulator of the Renin-Angiotensin System and Blood Pressure
- (2018) Ryousuke Satou et al. CURRENT HYPERTENSION REPORTS
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Innate Immune Signaling and Its Role in Metabolic and Cardiovascular Diseases
- (2018) Meng Xu et al. PHYSIOLOGICAL REVIEWS
- Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD
- (2017) Na Jiao et al. GUT
- The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis
- (2017) Feng-Juan Yan et al. HEPATOLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Reprogramming Innate Immune Signaling in Cardiometabolic Disease
- (2017) Yaxing Zhang et al. HYPERTENSION
- Sex Differences in Mechanisms of Hypertension Associated With Obesity
- (2017) Jessica L. Faulkner et al. HYPERTENSION
- Oxidative Stress, Inflammation, and Vascular Aging in Hypertension
- (2017) Tomasz J. Guzik et al. HYPERTENSION
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
- (2017) Paul K. Whelton et al. HYPERTENSION
- Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions
- (2017) et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study
- (2017) Dong Hyun Sinn et al. JOURNAL OF HEPATOLOGY
- Bi-directional analysis between fatty liver and cardiovascular disease risk factors
- (2017) Jiantao Ma et al. JOURNAL OF HEPATOLOGY
- Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease
- (2017) Roberto Lorbeer et al. JOURNAL OF HYPERTENSION
- Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies
- (2017) Fabrice Bonnet et al. JOURNAL OF HYPERTENSION
- Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver
- (2017) P. Dongiovanni et al. JOURNAL OF INTERNAL MEDICINE
- Association between vascular inflammation and non-alcoholic fatty liver disease: Analysis by 18F-fluorodeoxyglucose positron emission tomography
- (2017) Hyun Jung Lee et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4
- (2017) Guang-Nian Zhao et al. NATURE MEDICINE
- Beyond gut feelings: how the gut microbiota regulates blood pressure
- (2017) Francine Z. Marques et al. Nature Reviews Cardiology
- Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance
- (2017) Ruth C. R. Meex et al. Nature Reviews Endocrinology
- The role of chemokines in hypertension and consequent target organ damage
- (2017) Nathan P. Rudemiller et al. PHARMACOLOGICAL RESEARCH
- Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population
- (2017) Ren-Nan Feng et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Associations between polymorphisms of the ADIPOQ gene and hypertension risk: a systematic and meta-analysis
- (2017) Weina Fan et al. Scientific Reports
- Hepatic Oncostatin M Receptor β Regulates Obesity-Induced Steatosis and Insulin Resistance
- (2016) Pengcheng Luo et al. AMERICAN JOURNAL OF PATHOLOGY
- Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis
- (2016) Ling Gao et al. JOURNAL OF HEPATOLOGY
- DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity
- (2016) Lanfeng Xie et al. JOURNAL OF HEPATOLOGY
- Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications
- (2016) Sven M. Francque et al. JOURNAL OF HEPATOLOGY
- Association of blood pressure level with nonalcoholic fatty liver disease in nonhypertensive population
- (2016) Lin-Yan Qian et al. MEDICINE
- The impact of insulin resistance on the kidney and vasculature
- (2016) Ferruh Artunc et al. Nature Reviews Nephrology
- EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
- (2016) Obesity Facts
- Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling
- (2016) Pi-Xiao Wang et al. Nature Communications
- Hepatic TLR4 signaling in obese NAFLD
- (2015) Torfay Sharifnia et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: A prospective cohort study
- (2015) Tao Zhang et al. ATHEROSCLEROSIS
- The interferon regulatory factors as novel potential targets in the treatment of cardiovascular diseases
- (2015) Xiao-Jing Zhang et al. BRITISH JOURNAL OF PHARMACOLOGY
- Interferon Regulatory Factor Signalings in Cardiometabolic Diseases
- (2015) Xiao-Jing Zhang et al. HYPERTENSION
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Non-alcoholic fatty liver disease is associated with progression of arterial stiffness
- (2015) N. Li et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population
- (2015) Yongyuan Zhang et al. BMJ Open
- A Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG Study
- (2015) Ji Hye Huh et al. PLoS One
- The Role of Adiponectin in Endothelial Dysfunction and Hypertension
- (2014) Edward Rojas et al. CURRENT HYPERTENSION REPORTS
- Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis
- (2014) Carlos J Pirola et al. GUT
- Clinical association between non-alcoholic fatty liver disease and the development of hypertension
- (2014) Jae-Hong Ryoo et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension
- (2014) Ki-Chul Sung et al. JOURNAL OF HEPATOLOGY
- Clinical Significance of Non-Alcoholic Fatty Liver Disease as a Risk Factor for Prehypertension
- (2014) Jae-Hong Ryoo et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Homocysteine as a Risk Factor for Hypertension: A 2-Year Follow-Up Study
- (2014) Yixuan Wang et al. PLoS One
- The Clinical Investigation of Disparity of Nonalcoholic Fatty Liver Disease in a Chinese Occupational Population in Taipei, Taiwan
- (2013) Jui Wang et al. Asia-Pacific Journal of Public Health
- Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease
- (2013) Melania Gaggini et al. Nutrients
- Reversal of Vascular Macrophage Accumulation and Hypertension by a CCR2 Antagonist in Deoxycorticosterone/Salt-Treated Mice
- (2012) Christopher T. Chan et al. HYPERTENSION
- Elevated asymmetric dimethylarginine in plasma: An early marker for endothelial dysfunction in non-alcoholic fatty liver disease?
- (2011) Teoman Dogru et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase
- (2011) Alejandro López-Suárez et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Association between asymmetric dimethylarginine and indices of vascular function in patients with essential hypertension
- (2010) Martin Serg et al. BLOOD PRESSURE
- The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study
- (2010) Katharina Lau et al. JOURNAL OF HYPERTENSION
- Predicting Fibrosis Worsening in Obese Patients With NASH Through Parenchymal Fibronectin, HOMA-IR and Hypertension
- (2009) Paolo Sorrentino et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Mechanistic insights into the link between a polymorphism of the 3′UTR of theSLC7A1gene and hypertension
- (2008) Zhiyong Yang et al. HUMAN MUTATION
- The Prominent Role of the Liver in the Elimination of Asymmetric Dimethylarginine (ADMA) and the Consequences of Impaired Hepatic Function
- (2008) Milan C. Richir et al. JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started